

INTRODUCTION	3
1.1. Cancer	3
1.1.1. Therapeutic Interventions	5
1.2. Drug Delivery	7
1.2.1 Liposomes	8
1.2.2 Liposomes as Drug Carrier	10
1.2.3 Liposomes for Targeted Drug Therapy	11
1.2.4 Critical Parameters in Development of Targeted Liposomal Delivery System.....	15
1.2.5 Drug Loading in Liposomes	17
1.2.6 Drugs Suitable for Liposome Formulations.....	18
1.2.7 Drug Release	22
1.2.8 Factors Influencing In Vivo Behavior of Liposomes	23
1.2.9. Biological Stability of Liposomes.....	25
1.2.10 Problems Associated with Liposome Formulation Development	27
1.2.11 Freeze-Drying of Liposomes.....	29
1.2.12. Forthcoming Advances in Liposomal Drug Delivery.....	31
1.2.13 Drug Delivery to Solid Tumors	32
1.2.14 Effects of Irradiation on Tumor Vasculature.....	34
1.2.15 Targeted Drug Delivery to Irradiated Tumors.....	36
1.2.16 RGD Peptide.....	37
1.3 Gemcitabine Hydrochloride	38
1.3.1 Therapeutic Indications	38
1.3.2 Chemical Characteristics	38
1.3.3 Mechanism of Action	39
1.3.4 Metabolism.....	39
1.3.5 Toxicity	39
1.3.6 Properties of Gemcitabine HCl and Advantage of Liposomal Formulation.....	40
1.3.7 Approaches for Improving Formulation.....	40
1.4 Rationale, Hypotheses and Objective	41
1.4.1 Rationale	41
1.4.2 Hypothesis	41
1.4.3 Objective.....	41
1.5 REFERENCES.....	42

2.1 Introduction	55
2.2 Materials and Instruments	55
2.2.1 Instrument and Software for UV Spectrophotometric Measurement	55
2.2.2. Instrument and Software for HPLC Measurement	55
2.3 Materials and Reagents	55
2.4 Methods	56
2.4.1 Method Validation Parameters for UV Spectroscopic Method.....	56
2.4.2 Method Validation Parameters for HPLC Method.....	56
2.4.3 Direct Estimation of Gemcitabine HCl by UV Spectrometry	57
2.4.3.3. Estimation of Drug forIn VitroRelease Study Samples, Excipients and Formulations	57
2.4.4 Stability study	58
2.4.5 Interference study of the formulation component.....	58
2.4.6 Estimation of Gemcitabine HClby HPLC	58
2.4.6.1 Preparation of Stock Solution of Drug.....	58
2.4.6.2 Preparation of Standard Solutions of Drug	58
2.4.6.3 Estimation of Drug forIn VitroRelease Study Samples, Excipients and Formulations	58
2.5 Analytical Conditions.....	58
2.5.1 Chemicals and Reagents.....	59
2.6 Result & Discussion.....	59
2.6.1 Direct Estimation of Gemcitabine HCl by UV Spectrometry	59
2.6.2 Validation Parameters for UV Spectroscopic Method.....	61
2.6.3 Direct Estimation of Gemcitabine HCl by HPLC Method.....	65
2.6.4 Validation Parameters for HPLC Method	65
2.6.5 Intraday and Interday precision analysis.....	67
2.8 References	69

3. INTRODUCTION	72
3.1 Materials and Methods	77
3.1.1 Preparation of liposomes by thin film hydration method	78
3.2 Formulation Optimization of Gemcitabine liposomes.....	79
3.2.1 Optimization of Process and Formulation Variables	79
3.2.2 Optimization of Cholesterol levels.....	79
3.2.3 Preparation of PEGylated and Functionalised (RGD Grafting) liposomes	80
3.2.4 Lyophilization of GEM Liposomes	80
3.2.5 Entrapment Efficiency in Liposomes.....	81
3.2.6 Particle Size and Zeta Potential Analysis.....	81
3.2.7 Residual Water Content.....	82
3.2.8 Cryo-Transmission Electron Microscopy (Cryo-TEM)	82
3.2.9 Statistical Analysis.....	83
3.3 Results & Discussion	83
3.3.1 Selection of method for preparation of Gemcitabine HCl loaded liposomes	83
3.3.2 Preparation of liposomes by thin film hydration method	85
3.3.3 Formulation Optimization.....	86
3.4 Conclusion.....	98
3.5 REFERENCES.....	99

4.1. Cell-line Studies.....	107
4.2. In Vitro Cytotoxicity Assay (MTT Assay).....	109
4.2.1. Results and Discussion	110
4.3 In vitro Cell Uptake Studies.....	111
4.3.1 Preparation of Rhodimine loaded liposomes	111
4.3.2 Flow Cytometry.....	112
4.3.3 Confocal Microscopy.....	113
4.3.4 Sub-inhibitory concentration (Cell Cycle Analysis)	114
4.4 Results and Discussion	115
4.4.1. In vitro cell uptake	115
4.5. Chemosensitization Studies	122
4.5.1. Result and Discussion.....	123
4.6. In Vitro Drug Release.....	130
4.6.1 Results & Discussion.....	130
4.5. Haemolysis Study.....	131
4.5.1. Results and Discussion	133
4.6. Electrolyte induced flocculation test	134
4.7 References	137

5.1. Acute Toxicity Study.....	140
5.2. Description of the Methods.....	141
5.2.1. Selection of Animals Species.....	141
5.2.2. Housing and Feeding Conditions	141
5.2.3. Preparation of Animals	141
5.2.4. Preparation of Doses	142
5.2.5. Procedures.....	142
5.2.5.1. Administration of Doses.....	142
5.2.5.2. Sighting Study	142
5.2.5.3. MTD Determination	142
5.2.5.4. Numbers of Animals and Dose Levels	143
5.2.5.5. Observations	143
5.3. Results and Discussion.....	144
5.4. References	146
6. INTRODUCTION.....	148
6.1 Method	148
6.3 Results and Discussion	149
6.3.1 Stability Testing of RGD-grafted optimized Liposomes	149
6.4 References	151